| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| (verify) | |
Poly ICLC is an immunostimulant. It is polyinosinic-polycytidylic acid (poly I:C) mixed with the stabilizers carboxymethylcellulose and polylysine. It is under trial for use in cancer.
Poly I:C is a ligand for toll like receptor-3, which usually triggers on the structurally similar double-stranded RNA present in some viruses.
References
- ^ Zhu X, Nishimura F, Sasaki K, et al. (2007). "Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models". Journal of Translational Medicine. 5: 10. doi:10.1186/1479-5876-5-10. PMC 1802742. PMID 17295916.
- "Intervention Dynamic Trial Listing Page". National Cancer Institute. 13 June 2017.
External links
- National Cancer Institute: poly ICLC
| Immunostimulants (L03) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endogenous |
| ||||||||||||
| Exogenous | |||||||||||||
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |